87.7% complete response in 28 days

In a post by Jan-Henning Klusmann on LinkedIn, it says, “Great news from our Department of Pediatrics at Goethe-Universität Frankfurt and Universitätsklinikum Frankfurt am Main:
CD19 CAR T-cells 🛡 (Tisa-cel) show promise for relapsed B-lineage leukemia post-transplant 🧬:
✅87.7% complete response in 28 days
✅2-yr event-free survival 45.3%
🔑Better outcomes if relapse >6 months post-transplant.”

Source: Jan-Henning Klusmann/LinkedIn